Press release
Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market
Curious about the latest updates in the Osteosarcoma Pipeline? Click here to explore the therapies and trials making headlines @ Osteosarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Osteosarcoma Pipeline Report
* On 16 September 2025, Merck Sharp & Dohme LLC announced a study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
* DelveInsight's Osteosarcoma Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Osteosarcoma treatment.
* The leading Osteosarcoma Companies such as Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Promising Osteosarcoma Therapies such as Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.
Want to know which companies are leading innovation in Osteosarcoma? Dive into the full pipeline insights @ Osteosarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Osteosarcoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteosarcoma Pipeline Report also highlights the unmet needs with respect to the Osteosarcoma.
Osteosarcoma Overview
Osteosarcoma, also known as osteogenic sarcoma, is a rare type of bone cancer that originates in the bones, specifically affecting the long bones like those around the knee and shoulder. This cancer primarily develops in children and teenagers who are still growing. The exact cause of osteosarcoma is not fully understood, although in some instances, there is a familial predisposition with at least one gene associated with an increased risk. The hallmark symptom of osteosarcoma is pain, which can start intermittently but usually progresses to become constant.
Osteosarcoma Emerging Drugs Profile
* HS-20093: Hansoh BioMedical R&D Company
HS-20093 is a novel B7-H3-targeted antibody-drug conjugate that consists of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. This innovative drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, and other solid tumors through multiple phase I and II clinical trials in China. The mechanism of action (MOA) of HS-20093 involves the specific targeting of B7-H3, a transmembrane receptor highly prevalent on malignant cells, with the monoclonal antibody component. This targeting allows for the delivery of the topoisomerase inhibitor payload directly to the cancer cells, where it can exert its cytotoxic effects, potentially leading to tumor cell death and inhibition of tumor growth. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Osteosarcoma.
* ZN c3: Zentalis Pharmaceuticals
ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.
* NPX267: Nextpoint Therapeutics
NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3, the inhibitory receptor for the HHLA2 pathway (B7-H7), and is designed to prevent immune escape in solid tumors. By blocking the binding of KIR3DL3 on exhausted T and NK cells to HHLA2 expressed on tumor cells, NPX267 may be able to reactivate tumor antigen-primed immune cells in HHLA2-expressing solid tumors. Preventing KIR3DL3-mediated immune suppression may enhance anti-tumor immune responses for patients with HHLA2-positive cancers - a tumor antigen expressed independently of PD-L1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Osteosarcoma.
If you're tracking ongoing Osteosarcoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Osteosarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteosarcoma Companies
Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
Osteosarcoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Osteosarcoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Osteosarcoma Pipeline Report covers it all - check it out now @ Osteosarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Osteosarcoma Pipeline Report
* Coverage- Global
* Osteosarcoma Companies- Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
* Osteosarcoma Therapies- Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.
* Osteosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Osteosarcoma Treatment landscape in this detailed analysis @ Osteosarcoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Osteosarcoma: Overview
* Osteosarcoma Pipeline Therapeutics
* Osteosarcoma Therapeutic Assessment
* Osteosarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HS-20093: Hansoh BioMedical R&D Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* NPX267: Nextpoint Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteosarcoma Key Companies
* Osteosarcoma Key Products
* Osteosarcoma- Unmet Needs
* Osteosarcoma- Market Drivers and Barriers
* Osteosarcoma- Future Perspectives and Conclusion
* Osteosarcoma Analyst Views
* Osteosarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteosarcoma-pipeline-insights-report-2025-by-delveinsight-mapping-innovative-rd-strategies-clinical-advancements-pharma-leadership-and-future-growth-potential-in-the-therapeutics-market]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteosarcoma Pipeline Insights Report 2025 by DelveInsight: Mapping Innovative R&D Strategies, Clinical Advancements, Pharma Leadership, and Future Growth Potential in the Therapeutics Market here
News-ID: 4190578 • Views: …
More Releases from ABNewswire
Innovative Connections Adds Six New Experts To The Team
FORT COLLINS, Colo. - Dec. 17, 2025 - Innovative Connections [https://innovativeconnectionsinc.com/], a leadership consulting firm dedicated to transforming organizations through connection, purpose, and courageous leadership, has added six new professionals to the team.
The six new consultants, JoAnn Auger, John P. Broschak, Tim Smith, Donna Pearring, JoEllen Wilkins and Debby Neely, bring years of experience from small businesses, Fortune 500s, construction, insurance, financial institutions and engineering.
*
JoAnn Auger: JoAnn brings over 30…
Certificate Authority Market to Reach USD 359.40 Million by 2030 | Driven by Clo …
Mordor Intelligence has published a new report on the Certificate Authority Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Certificate Authority Market Overview
The certificate authority market [https://www.mordorintelligence.com/industry-reports/certificate-authority-market?utm_source=abnewswire] is poised for significant growth over the next few years, with an estimated market size of USD 208.68 million in 2025 and a forecasted value of USD 359.40 million by 2030, reflecting a CAGR of 11.49%. This growth is primarily…
Copenhagen Emerges as a Popular Destination for Secret and Surprise Engagement P …
Copenhagen is seeing increased interest from international couples planning secret and surprise engagement proposals. This release features Copenhagen photographer Aleks Jakobsons, who photographs dozens of proposals each year, and outlines why couples choose the city for its atmosphere, accessibility, and personalised proposal planning supported by local expertise.
Copenhagen, Denmark - December 17, 2025 - Copenhagen is increasingly on the radar of couples who want to combine travel with one of the…
DermaStation Skin Clinic leverages superior-grade laser technology for enhanced …
The popular Delhi-based skin clinic aims to make pigmentation treatment highly safe and effective.
In a bid to ensure better and surprising results to its clients, DermaStation, a leading skin clinic in Delhi leverages advanced laser technologies for focused pigmentation treatment in Delhi [https://www.dermastation.com/pigmentation+treatment+in+delhi+hyperpigmentation+treatment+delhi.html].
The expert dermatologists at DermaStation by leveraging the all-new highly-innovative laser dermatology suite, aims to deliver better results to clients struggling with mild to hyper pigmentation.
Speaking about the…
More Releases for Osteosarcoma
Osteosarcoma Drug Market Hits New High | Major Giants AstraZeneca,Pfizer,Amgen,
HTF MI just released the Global Osteosarcoma Drug Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in Osteosarcoma Drug Market are: Pfizer, Amgen, Bayer,…
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuti …
The Osteosarcoma market growth is driven by factors like increase in the prevalence of Osteosarcoma, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Osteosarcoma market report [https://www.delveinsight.com/report-store/osteosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Osteosarcoma market size, share, Osteosarcoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteosarcoma market…
Exploring the Osteosarcoma Drug Market: Trends, Opportunities, and Challenges
Osteosarcoma, a rare and aggressive bone cancer primarily affecting adolescents and young adults, has garnered significant attention in the pharmaceutical sector due to its complex treatment requirements and evolving drug landscape. This guest post delves into the osteosarcoma drug market, providing insights into its current state, opportunities, challenges, and future trends.
Introduction
Osteosarcoma is the most common primary malignant bone tumor, often occurring in the long bones of the arms and legs.…
Osteosarcoma Market Size, Share, Trends & Forecast - 2034
Overview:
According to the IMARC Group, the osteosarcoma market exhibited a market size of US$ 880.9 Million in the year 2023 and is projected at a CAGR of 4.68% during 2024-2034. This can be attributed to the growing use of combination therapy involving neoadjuvant chemotherapy and surgical resection, which improves treatment outcomes in patients and reduces the risk of cancer relapse.
The osteosarcoma market report offers a comprehensive analysis of the market…
Osteosarcoma Market Report 2023-2033 | Industry Size, Growth and Latest Insights
Market Overview:
The osteosarcoma market is expected to exhibit a CAGR of 4.87% during 2023-2033. The report offers a comprehensive analysis of the osteosarcoma market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally,…
Pediatric Osteosarcoma Therapeutics Market Insights, Forecast to 2031
The report extensively examines the global Pediatric Osteosarcoma Therapeutics market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Pediatric Osteosarcoma Therapeutics. For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global…
